obesity treatment – The Milli Chronicle

Saturday, November 8, 2025

Latest:

Wall Street Market Adjustments Reflect Broader Economic Considerations
Gates Foundation Commits $1.4 Billion to Support Climate-Resilient Farming
U.S. Emphasizes Energy Security Through Balanced Approach to Oil, Gas, and Renewables
US Government Launches Generous Model to Cut Medicaid Prescription Costs
Wall Street Applauds Tesla Shareholders’ Landmark Approval of Elon Musk’s $1 Trillion Performance-Based Pay Package

Factual Version of a Story

NewsDesk Milli Chronicle November 7, 2025November 7, 2025 Cipla, diabetes care India, diabetes control, diabetes treatment India, Eli Lilly, Eli Lilly India, GLP-1 drugs, healthcare growth India, healthcare technology, Hyderabad health innovation, India pharma market, medical innovation, metabolic health, Mounjaro, Novo Nordisk, obesity awareness, obesity treatment, pharmaceutical sales India, Wegovy, weight management therapy, weight-loss drug India, weight-loss injection

Eli Lilly’s Mounjaro Becomes India’s Top-Selling Drug, Signaling a New Era in Healthcare Innovation

Hyderabad – Eli Lilly’s groundbreaking weight-loss and diabetes treatment, Mounjaro, takes the top spot in India’s pharmaceutical market, marking a

U.S. Strikes Breakthrough Deal to Boost Access to Weight-Loss Drugs

A landmark public-private partnership aims to make life-changing obesity and diabetes treatments more affordable and accessible for millions across America.

Pfizer Strengthens Its Bid for Metsera, Reinforces Commitment to Innovation in Obesity Treatment

Pfizer’s strategic move to revise its bid for Metsera underscores its dedication to advancing next-generation obesity therapies and fostering competition

Novo Nordisk Restructures for Future Growth, Streamlines U.S. Operations to Strengthen Global Efficiency

London — Global healthcare leader Novo Nordisk has taken decisive steps to streamline its U.S. manufacturing operations as part of